Skip to search formSkip to main contentSkip to account menu

100 ML Immunoglobulin G, Human 100 MG/ML Injection [Privigen]

Known as: Privigen 10 GM per 100 ML Injection, privigen 10 % in 100 ML Injection, Human Immunoglobulin G 10 g in 100 mL INTRAVENOUS LIQUID [Privigen] 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract This prospective, Phase 3, open-label, study (EudraCT: 2016-001631-12) evaluated pharmacokinetic (PK) characteristics of… 
2016
2016
BackgroundHemolysis, a rare but potentially serious complication of intravenous immunoglobulin (IVIG) therapy, is associated with… 
2014
2014
This retrospective study evaluated the effectiveness and tolerability in clinical practice of an L-proline–stabilized 10… 
Highly Cited
2013
Highly Cited
2013
This prospective, multicenter, single‐arm, open‐label Phase III study aimed to evaluate the efficacy and safety of Privigen® (10… 
2012
2012
BackgroundMultiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as… 
2011
2011
  • M. Berger
  • Immunotherapy
  • 2011
  • Corpus ID: 31651592
Liquid IgG preparations are preferred over lyophilized preparations because reconstitution is not required. Formation of dimers… 
2010
2010
PurposeThe tolerability of L-proline-stabilized Privigen®, a new 10% liquid immunoglobulin for intravenous administration, was… 
2009
2009
The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen… 
Highly Cited
2008
Highly Cited
2008
PurposeThe present study was designed to evaluate the efficacy and safety of a novel, 10% liquid formulation of intravenous…